Compare TECH & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TECH | MBLY |
|---|---|---|
| Founded | 1976 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 9.1B |
| IPO Year | 1995 | 2022 |
| Metric | TECH | MBLY |
|---|---|---|
| Price | $51.74 | $9.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 20 |
| Target Price | ★ $71.82 | $14.13 |
| AVG Volume (30 Days) | 2.8M | ★ 6.0M |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | ★ 0.62% | N/A |
| EPS Growth | N/A | ★ 87.43 |
| EPS | ★ 0.81 | N/A |
| Revenue | $1,219,635,000.00 | ★ $1,894,000,000.00 |
| Revenue This Year | $2.49 | $4.91 |
| Revenue Next Year | $6.40 | $13.94 |
| P/E Ratio | $65.60 | ★ N/A |
| Revenue Growth | 5.23 | ★ 14.51 |
| 52 Week Low | $43.20 | $6.47 |
| 52 Week High | $72.16 | $20.18 |
| Indicator | TECH | MBLY |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 44.70 |
| Support Level | $49.98 | $8.43 |
| Resistance Level | $57.86 | $9.62 |
| Average True Range (ATR) | 1.88 | 0.56 |
| MACD | 0.81 | -0.08 |
| Stochastic Oscillator | 84.03 | 7.80 |
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Moovit. The solutions provided by the company are: Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.